- Home
- DXYZ vs MLYS Comparison
DXYZ vs MLYS Comparison
Compare DXYZ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | MLYS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 2.4B |
| IPO Year | 2024 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | MLYS |
|---|---|---|
| Price | $25.74 | $27.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 622.2K | ★ 1.0M |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.71 | $10.44 |
| 52 Week High | $50.50 | $47.65 |
Technical Indicators
Market Signals| Indicator | DXYZ | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 41.11 |
| Support Level | $23.35 | $26.85 |
| Resistance Level | $28.23 | $30.05 |
| Average True Range (ATR) | 1.06 | 1.76 |
| MACD | -0.19 | 0.08 |
| Stochastic Oscillator | 14.58 | 29.78 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.